GURUFOCUS.COM » STOCK LIST » USA » NAS » Cullinan Oncology Inc (NAS:CGEM) » Definitions » Earnings Yield (Joel Greenblatt) %
Switch to:

Cullinan Oncology (NAS:CGEM) Earnings Yield (Joel Greenblatt) %

: -909.09% (As of Sep. 2022)
View and export this data going back to 2021. Start your Free Trial

Cullinan Oncology's Enterprise Value for the quarter that ended in Sep. 2022 was $15.16 Mil. Cullinan Oncology's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-133.88 Mil. Cullinan Oncology's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2022 was -909.09%.

The historical rank and industry rank for Cullinan Oncology's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

CGEM' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -53.37   Med: -21.96   Max: 112.36
Current: 108.7

During the past 4 years, the highest Earnings Yield (Joel Greenblatt) of Cullinan Oncology was 112.36%. The lowest was -53.37%. And the median was -21.96%.

CGEM's Earnings Yield (Joel Greenblatt) % is ranked better than
90.46% of 1573 companies
in the Biotechnology industry
Industry Median: -10.12 vs CGEM: 108.70

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Cullinan Oncology's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2022 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Cullinan Oncology Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Cullinan Oncology's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Oncology Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Earnings Yield (Joel Greenblatt) %
- - - -17.27

Cullinan Oncology Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Earnings Yield (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.42 -17.27 -65.36 434.78 -909.09

Competitive Comparison

For the Biotechnology subindustry, Cullinan Oncology's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Cullinan Oncology Earnings Yield (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, Cullinan Oncology's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Cullinan Oncology's Earnings Yield (Joel Greenblatt) % falls in comparison to its industry or sector. The grey bar indicates the Earnings Yield (Joel Greenblatt) %'s extreme value range as defined by GuruFocus.



Cullinan Oncology Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Cullinan Oncologys Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2021 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-67.954/393.364103
=-17.28 %

Cullinan Oncology's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-133.88 Mil.



Cullinan Oncology  (NAS:CGEM) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Cullinan Oncology Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Cullinan Oncology's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cullinan Oncology (NAS:CGEM) Business Description

Cullinan Oncology logo
Industry
Traded in Other Exchanges
N/A
Address
One Main Street, Suite 520, Cambridge, MA, USA, 02142
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
Executives
David P. Ryan director C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Jacquelyn L Sumer officer: Chief Legal Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Anne-marie Martin director ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Jeffrey Alan Jones officer: Chief Medical Officer ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Nadim Ahmed director, officer: President and CEO C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901

Cullinan Oncology (NAS:CGEM) Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership